Search
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalCorifollitropin alfa is produced by a method known as ‘recombinant DNA technology’. … This means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270].
Products: GONAL -F ® INYECTOR 450 UI (33MCG)/0.75ML., GONAL-F ® INYECTOR 900 UI (66 MCG)/1.5 MLNicotine
go.drugbank.com/drugs/DB00184ApprovedInvestigationalNicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of it...
Products: Up and Up Nicotine, Up and Up nicotineHuman thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalFurthermore, human thrombin is manufactured by chromatographic purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride [FDA Label]. … Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin.
Products: THROMBIRAAS1000 UITuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalIt was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. … Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.
Products: ESPEROCT® 1500 UI, ESPEROCT® 2000 UIMethoxy polyethylene glycol-epoetin beta
go.drugbank.com/drugs/DB09107ApprovedInvestigationalMethoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease...
Products: MIRCERA 100 UG/0.3ML, MIRCERA 120 UG/0.3MLSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedThe harvested product is concentrated and purified by a series of chromatography steps. … acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length plasma-derived FVIII, has been deleted and replaced by
Products: NUWIQ 500 UI, NUWIQ 2000 UIHomosalate
go.drugbank.com/drugs/DB11064ApprovedSalicylates prevent direct skin exposure to the sun’s harmful rays by absorbing ultraviolet (UV) light.
Mixtures: Sei Bella Daytime Delivery, Sei Bella Daytime DeliveryProducts: dAlba Vegan Tone-Up SunscreenBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approvedCombination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist … [A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such
Products: TRANSTEC 35 UG, TRANSTEC 70 UGCholecalciferol
go.drugbank.com/drugs/DB00169ApprovedInvestigationalNutraceuticalAppropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a healthy physiologic range to sustain a variety of metabolic functions, transcription regulation
Mixtures: CALCIBON® D 800 UI TABLETAS RECUBIERTAS, CALCIBON® D 800 UI TABLETAS RECUBIERTASProducts: DECAL® 2000 UI, DECAL® 5000 UIEftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedEftrenonacog alfa was developed and marketed as Alprolix for intravenous injection by Biogen. It was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … It is an X-linked genetic disease caused by mutation of the gene for coagulation protein factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding
Products: ALPROLIX® 250 UI